Cabaletta Bio, Inc. financial data

Symbol
CABA on Nasdaq
Industry
Biological Products, (No Diagnostic Substances)
Location
2929 Arch Street, Suite 600, Philadelphia, PA
State of incorporation
DE
Fiscal year end
December 31
Latest financial report
10-K - Q4 2024 - Mar 31, 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 916 % -40.6%
Debt-to-equity 13.3 % +69.3%
Return On Equity -62 % -51.8%
Return On Assets -54.7 % -44.5%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 50.7M shares +5.19%
Common Stock, Shares, Outstanding 48.9M shares +17.3%
Entity Public Float 350M USD -29.2%
Common Stock, Value, Issued 1K USD
Weighted Average Number of Shares Outstanding, Basic 1.17M shares -71.7%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense 97.2M USD +75.4%
General and Administrative Expense 27.9M USD +45.2%
Operating Income (Loss) -125M USD -67.6%
Income Tax Expense (Benefit) 0 USD
Net Income (Loss) Attributable to Parent -116M USD -71.2%
Earnings Per Share, Basic -2.34 USD/shares -41.8%
Earnings Per Share, Diluted -2.34 USD/shares -41.8%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 164M USD -15.2%
Cash, Cash Equivalents, and Short-term Investments 164M USD -32%
Assets, Current 167M USD -31.8%
Property, Plant and Equipment, Net 2.74M USD +7.95%
Operating Lease, Right-of-Use Asset 6.32M USD +28.6%
Other Assets, Noncurrent 2.29M USD +34.2%
Assets 185M USD -27%
Accounts Payable, Current 4.92M USD +8.27%
Employee-related Liabilities, Current 8.32M USD +59.9%
Liabilities, Current 27.1M USD +69.4%
Operating Lease, Liability, Noncurrent 2.38M USD +63.5%
Liabilities 32.7M USD +87.4%
Accumulated Other Comprehensive Income (Loss), Net of Tax 0 USD -100%
Retained Earnings (Accumulated Deficit) -349M USD -49.7%
Stockholders' Equity Attributable to Parent 152M USD -35.5%
Liabilities and Equity 185M USD -27%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -24M USD -90.3%
Net Cash Provided by (Used in) Financing Activities 6.86M USD +2933%
Net Cash Provided by (Used in) Investing Activities -812K USD -103%
Common Stock, Shares Authorized 150M shares 0%
Common Stock, Shares, Issued 48.9M shares +17.3%
Deferred Tax Assets, Valuation Allowance 111M USD +52.6%
Deferred Tax Assets, Gross 115M USD +54.9%
Operating Lease, Liability 0 USD
Depreciation 393K USD +7.67%
Payments to Acquire Property, Plant, and Equipment 812K USD +114%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -116M USD -71.5%
Lessee, Operating Lease, Liability, to be Paid 6.37M USD
Property, Plant and Equipment, Gross 8.25M USD +30.2%
Operating Lease, Liability, Current 3.99M USD +12%
Operating Lease, Weighted Average Discount Rate, Percent 0.11 pure +21.1%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 626K USD +69.2%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 10M shares 0%
Unrecognized Tax Benefits 0 USD
Operating Lease, Payments 1.25M USD +120%
Preferred Stock, Shares Outstanding 0 shares
Deferred Tax Assets, Net of Valuation Allowance 3.94M USD +172%
Operating Leases, Future Minimum Payments Due 5.02M USD -2.34%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%